|

Efineptakin alfa Clinical Trials

1 actively recruiting trial across 1 location

Also known as: GX-I7, Hyleukin-7 (TM), IL-7-hyFc, Il-7 Hybrid Fc, NT-I7 +4 more

Pipeline

Phase 2: 1

Top Sponsors

  • Mayo Clinic1

Indications

  • High Grade Astrocytic Tumor1
  • Recurrent Glioblastoma, IDH-Wildtype1
  • Recurrent Gliosarcoma1
  • Cancer1

Rochester, Minnesota1 trial

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Mayo Clinic

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.